Meta-analysis: SGLT2 inhibitors reduce heart failure or CV death in type 2 diabetes

The study

This is a meta-analysis of randomised controlled trials, published in Diabetes, Obesity & Metabolism. The authors searched PubMed, Web of Science, Scopus and CENTRAL from inception through 15 May 2026.

They included large placebo-controlled trials (at least 1000 participants) and prespecified subgroup analyses in adults with type 2 diabetes. The primary outcome was the composite of first hospitalisation for heart failure (HHF) or cardiovascular (CV) death. Secondary outcomes were 3-point major adverse cardiovascular events (MACE), CV death, myocardial infarction (MI), stroke, first HHF and composite kidney outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) came from random-effects inverse-variance models.

What they found

Fourteen studies were included, with 76 969 patients (41 761 on an SGLT2 inhibitor and 35 208 on placebo).

• Primary composite: SGLT2 inhibitors reduced it by 23% (HR 0.77, 95% CI 0.73-0.81, p < 0.0001; I2 = 0%).
• Subgroups: The effect did not differ significantly by baseline heart failure (p-interaction = 0.82) or established ASCVD (p-interaction = 0.46).
• MACE: Reduced by 14% (HR 0.86, 95% CI 0.81-0.92).
• CV death: HR 0.86 (95% CI 0.79-0.93).
• MI: HR 0.88 (95% CI 0.81-0.96).
• Stroke: Not significantly different (HR 0.93, 95% CI 0.81-1.08).
• First HHF: Reduced by 29% (HR 0.71, 95% CI 0.66-0.77).
• Composite kidney outcomes: Reduced by 31% (HR 0.69, 95% CI 0.60-0.79). The authors note moderate heterogeneity for kidney outcomes.

How much weight to give it

The authors describe the protection as consistent and clinically meaningful across the full range of cardiovascular and renal risk. The pooled data come from randomised, placebo-controlled trials. For the primary result, the confidence interval was narrow and I2 was 0%, which points to little heterogeneity between trials on that outcome.

There are limits. The authors themselves say the ertugliflozin estimate and the moderate heterogeneity in kidney outcomes need careful reading. They point to trial-level clinical differences and nonstandard kidney endpoint definitions. So the kidney result is less certain than the primary result.

The abstract does not report several things: funding, follow-up length, risk-of-bias assessment, drug-specific estimates, or safety and adverse events. It reports interaction tests only for baseline heart failure and established ASCVD. Only large trials were eligible, so smaller studies are not represented.

The authors conclude that their findings support proactive, guideline-concordant initiation of evidence-based SGLT2 inhibitors as foundational therapy. That is a recommendation from the authors. It goes beyond the effect estimates, because the abstract gives no data on harms or on cost.

For your clinic

The results are consistent with the idea that SGLT2 inhibitors protect the heart and kidneys in type 2 diabetes. According to the interaction tests, this applies to people with and without heart failure or established ASCVD at baseline. The abstract reports no significant effect on stroke.

These findings can support discussion of the class in people with type 2 diabetes and cardiorenal risk. They do not replace individual assessment. Safety, tolerability, kidney function thresholds and cost are not covered in the abstract. Read the full paper and current guidelines before changing practice, especially on drug-specific choices and kidney outcome definitions.